Scotts Miracle-Gro (SMG) Q1 2026 earnings review
Finally a Pure Play: Hawthorne Exit and Buybacks Eclipse Sales Dip
Scotts Miracle-Gro is finally executing the strategic divorce investors have waited for. The company announced advanced discussions to divest Hawthorne to Vireo Growth, classifying it as Discontinued Operations effective immediately. While Q1 headline revenue fell 3% due to retailer order timing, the 'pure play' consumer narrative is taking shape with a new $500M share repurchase program. Profitability improved despite lower volume, with Gross Margin expanding 90 bps to 25.0%. Management reaffirmed all FY26 guidance, signaling that the Q1 sales air pocket is temporary.
🐂 Bull Case
The long-awaited divestiture of the volatile Hawthorne cannabis business is in 'advanced discussions.' By classifying it as discontinued operations, SMG immediately cleans up its margin profile and removes the primary drag on valuation multiples.
The Board authorized a new $500M share repurchase program, signaling the end of the deleveraging crisis mode. With leverage down to 4.03x (from >5x peak), management is pivoting back to shareholder returns.
🐻 Bear Case
U.S. Consumer sales fell 4% YoY in Q1. While management blames shipment timing, the company needs a significant acceleration in Q2/Q3 to meet its 'low single-digit growth' guidance for the year.
By missing growth in Q1 (historically a smaller quarter), the burden of performance now rests entirely on the spring season. Any weather adverse events in Q2/Q3 will make FY26 guidance mathematically impossible to hit.
⚖️ Verdict: 🟢
Bullish. The sales miss looks like noise; the structural improvements (Hawthorne exit, margin expansion, buybacks) are the signal. SMG is returning to its historical status as a stable, high-margin compounder.
Key Themes
The Hawthorne Divorce
Management pulled the trigger on classifying Hawthorne as 'Held for Sale/Discontinued Operations.' The unit is being sold to Vireo Growth. This is a transformative accounting change that immediately accreted margins and allows investors to value SMG as a pure-play consumer staple rather than a hybrid cannabis supplier.
Gross Margin Expansion
Accelerating. GAAP Gross Margin improved 90 basis points YoY to 25.0% (Adjusted 25.4%). This expansion occurred despite negative fixed-cost leverage from lower sales volume, indicating strong underlying improvements in pricing and product mix (shifting away from low-margin commodities like mulch).
U.S. Consumer Sales Dip
Decelerating. U.S. Consumer sales dropped 4% to $328.5M. Management attributes this to retailer ordering patterns (shifting inventory load-in closer to the spring season). While plausible, this creates a 'hockey stick' requirement for the rest of the year to hit the 'low single-digit' growth target.
Capital Allocation Pivot
For the first time in nearly two years, the conversation shifted from 'debt paydown' to 'shareholder returns.' A $500M buyback authorization was approved. While actual buying won't start until 'late 2026,' the authorization itself serves as a floor for the stock and a signal of management confidence in cash flow sustainability.
Operating Leverage Lag
While Gross Margins improved, the bottom line is still in the red for Q1 (seasonal norm). Adjusted EBITDA improved slightly to $3.0M from $0.9M. However, SG&A expenses were $106.0M. The company needs significant volume in Q2/Q3 to cover this fixed base; the Q1 volume decline prevented more meaningful EBITDA expansion.
Other KPIs
Improving. Loss narrowed by $0.11 compared to $(0.88) in the prior year. This was driven by the 90 bps gross margin improvement and tight cost controls, despite the revenue headwind.
Improving. Down from 4.52x a year ago. Management targets 'high 3s' by the end of FY26. The rapid deleveraging phase is mostly complete, allowing the pivot to buybacks.
Stable. The company reaffirmed this target. Achieving this while restarting buybacks suggests confidence in working capital efficiency.
Guidance
Stable/Reaffirmed. Implies acceleration. Given the -4% start in Q1, the company effectively needs mid-single-digit growth in Q2/Q3 to hit this target. Dependence on weather and the 'lawn reinvention' strategy is high.
Stable/Reaffirmed. The Q1 result of 25.4% is seasonally lower (due to mix) but the 90 bps YoY improvement keeps them on track to hit the full-year target, which relies on higher-margin chemical sales in Q2/Q3.
Stable/Reaffirmed. This range implies significant profitability in the spring. The removal of Hawthorne losses (now discontinued) provides a tailwind to the 'Continuing Operations' EPS number.
Stable/Reaffirmed. Consistent with the modest top-line growth and margin expansion story.
Key Questions
Q1 Sales vs. Replenishment Reality
Management cited retailer order timing for the 4% drop in U.S. Consumer sales. Can you quantify the discrepancy between 'sell-in' (your revenue) and 'sell-through' (POS) at retail during the quarter to validate this claim?
Vireo Deal Specifics
Regarding the Hawthorne sale to Vireo Growth: Does the 'investment in Vireo' received in exchange create a new lock-up period or liquidity risk, or will Scotts be able to monetize that stake immediately?
Buyback Timing
The buyback is authorized now but commences 'late 2026.' Is this delay solely due to covenant restrictions or a desire to see the spring season results first?
Margin Bridge
With Hawthorne moved to discontinued ops, the corporate gross margin structure changes. How much of the 90bps Q1 margin improvement was organic operational efficiency versus simply removing the lower-margin Hawthorne mix?